AF
CLVS

Amalgamated Financial’s Clovis Oncology, Inc. CLVS Stock Holding History

Amalgamated Financial’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$37K Buy
+18,424
New +$36.2K ﹤0.01% 2556

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Amalgamated Financial's CLVS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Clovis Oncology, Inc. (CLVS) in Q1 2022: 18,424 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #2556 among its holdings.

153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • Amalgamated Financial held 18,424 shares of Clovis Oncology, Inc. worth $37K as of Q1 2022.
  • Clovis Oncology, Inc. was a new Amalgamated Financial position in Q1 2022.
  • Clovis Oncology, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2556 holding.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.